NIH Research
NIH researchers identify avenue for enhanced GLP-1-induced weight loss
Modulating intracellular signaling may extend drug effects.
Clinical & Research · page 65
New research and findings from open-access journals and the U.S. research agencies.
NIH Research
NIH-supported project expands access to care for children with amblyopia
Open-access tool guides eye doctors without specific pediatric eye care training in amblyopia diagnosis and management.
NIH Research
NIH-funded study maps human pancreatic islet cells, offering new clues to diabetes risk
Comprehensive characterization of islet cells facilitated by national organ donation program.
NIH Research
Researchers develop innovative model for risk assessment for hypertrophic cardiomyopathy
NIH-funded study incorporates new measures to better predict outcomes in chronic heart condition.
NIH Research
Oral small-molecule GLP-1 drugs penetrate deep into the brain to suppress cravings
NIH-funded research identifies new mechanism of action for next-generation weight-loss drugs.
ACC (Cardiology)
Stylet-Driven vs. Non-Stylet-Driven Leads For Conduction System Pacing | NCDR Study
Both stylet-driven and non-stylet-driven leads for conduction system pacing (CSP) exhibited high implant success and low complication rates, highlighting the safety and effectiveness of both lead types, according to a recent study published in Heart Rhythm.
Fierce Biotech
Why City of Hope Built a National Clinical Trials Platform Designed to Scale With Oncology Innovation
City of Hope built a national trials engine to move oncology innovation faster, wider and with the scale sponsors need.
Fierce Biotech
Roche bets $700M upfront on Nurix’s late-phase BTK degrader to tee up Lilly showdown
Roche is paying Nurix Therapeutics $700 million upfront for rights to bexobrutideg, securing a stake in a BTK degrader that is set to go head-to-head against Eli Lilly’s Jaypirca in a phase 3 trial.
Fierce Biotech
ADA: Boehringer execs claim survodutide tolerability 'consistent' with class despite phase 3 update
A deeper dive into survodutide’s performance could undercut the GLP-1/glucagon drug’s competitiveness on raw weight loss and tolerability.
Fierce Biotech
ADA: AZ’s oral GLP-1 shows ‘competitive efficacy’ in phase 2, setting stage for pivotal program
With a pair of phase 2 readouts, AstraZeneca is positioning itself to potentially capture a portion of the oral GLP-1 market. Up next, its elecoglipron is heading into pivotal studies.
Fierce Biotech
Bial bails after Parkinson’s fail, axing asset over phase 2 miss
Bial has stopped development in a subpopulation of Parkinson’s disease patients after its phase 2b trial missed its primary and key secondary efficacy endpoints.
ACC (Cardiology)
Optimizing Dual Antiplatelet Therapy in Patients With Diabetes and Multivessel Disease Undergoing PCI: The TUXEDO-2 Trial
The TUXEDO-2 (Ultrathin Strut vs. Xience in a Diabetic Population With Multivessel Disease 2—India Study) trial demonstrated that among patients with diabetes mellitus and multivessel coronary artery disease undergoing percutaneous coronary intervention (PCI)...
Fierce Biotech
Sanofi halts phase 3 autoimmune trial early over insufficient efficacy as pipeline woes continue
Sanofi has stopped a phase 3 autoimmune clinical trial early after an interim analysis found the therapy was “unlikely to provide sufficient efficacy.” The setback eliminates one opportunity for a key late-phase program and continues the “bumpy ride” for Sanofi’s pipeline.
Fierce Biotech
Takeda’s TYK2 inhibitor beats Bristol Myers’ Sotyktu in phase 3 psoriasis showdown
Takeda has won the battle of the TYK2 inhibitors, toppling Bristol Myers Squibb’s Sotyktu to strengthen its hand ahead of an anticipated plaque psoriasis launch next year.
Fierce Biotech
Caribou boosts case that off-the-shelf CAR-T matches autologous drugs ahead of phase 3
Caribou Biosciences has linked its CAR-T cell therapy candidate to 17.1-month median progression-free survival, adding to evidence that the off-the-shelf treatment can match the efficacy of autologous products in lymphoma patients.
NIH Research
NIH research establishes new framework for the role of senescence in aging
First large-scale atlas of senescent cells could help inform future therapies for age-related diseases.
Fierce Biotech
Novo reports data breach, tells clinical trial patients to 'remain vigilant'
As cybersecurity threats have proliferated across industries in recent years, biopharma companies have emerged as prominent targets, with intellectual property, patient data and other sensitive information at stake. Now, Novo Nordisk is the latest drug giant to report a data breach.
ACC (Cardiology)
CKD Studies Spotlight GFR Measurement, Finerenone Benefit and Rivaroxaban Risk
Research presented at the European Renal Association Congress, held June 3-6 in Glasgow, Scotland, highlighted new findings in chronic kidney disease (CKD), including evidence supporting more precise GFR assessment and trial results on finerenone in nondiabetic CKD and rivaroxaban in advanced CKD patients with CV risk factors.
NIH Research
Dr. Raymond Jacobson selected as director of the NIH Center for Scientific Review
The Center ensures NIH grant applications receive fair, independent, expert, and timely reviews.
Fierce Biotech
Soligenix axes lymphoma program after phase 3 setback, mulls M&A options
Soligenix has scrapped its cutaneous T-cell lymphoma program in the wake of a phase 3 setback, leaving the biotech focused on another rare disease prospect and considering strategic alternatives.
NIH Research
NIH launches new office to advance human-based research and reduce animal use
New office will coordinate efforts to develop, validate and scale animal-free research models.
Fierce Biotech
Traws defers midphase flu study after negative regulatory review
U.K. regulators have issued a “negative review” of Traws Pharma’s planned human influenza challenge study, forcing the biotech to defer a phase 2a trial tied to $20 million in funding.
Fierce Biotech
Intellia touts ‘paradigm-shifting’ phase 3 data for one-time HAE treatment
Six weeks after Intellia Therapeutics reported that it met its primary endpoint in a phase 3 trial of its in vivo gene-editing therapy lonvoguran ziclumeran (lonvo-z) for patients with hereditary angioedema (HAE), the company released additional positive data showing that the study also met its secondary endpoints with statistical and clinical significance.
NIH Research
For adults with prediabetes, lifestyle intervention lowered risk of developing multiple chronic conditions
NIH-supported, long-term clinical trial found no difference between metformin and placebo.